Janssen Settles Risperdal Allegations

Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, has settled allegations with 36 states and the District of Columbia regarding allegations related to promotional and marketing practices for its antipsychotic drug Risperdal.
 
The company will pay approximately $181 million as part of a consent decree to resolve state consumer protection law claims in the 36 states and the District of Columbia. The company agreed to the settlement to resolve the concerns and to avoid unnecessary expense and a prolonged legal process, but does not admit to any wrongdoing or violation of any law or regulation.
 
“We have chosen this path to achieve a prompt and full resolution of these state claims and to ensure we continue to focus on our mission of providing medicines to meet the significant unmet needs of many people who suffer from mental illness,” said Michael Yang, president, Janssen Pharmaceuticals, Inc.
 
As part of the settlement, Janssen reaffirmed it would not promote any of its atypical antipsychotics for off-label uses or make any false or misleading claims related to those products.